- Home
- UBX vs CLDI Comparison
UBX vs CLDI Comparison
Compare UBX & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBX
- CLDI
- Stock Information
- Founded
- UBX 2009
- CLDI 2014
- Country
- UBX United States
- CLDI United States
- Employees
- UBX N/A
- CLDI N/A
- Industry
- UBX Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UBX Health Care
- CLDI Health Care
- Exchange
- UBX Nasdaq
- CLDI Nasdaq
- Market Cap
- UBX 16.5M
- CLDI 18.1M
- IPO Year
- UBX 2018
- CLDI N/A
- Fundamental
- Price
- UBX $1.73
- CLDI $0.89
- Analyst Decision
- UBX Strong Buy
- CLDI Strong Buy
- Analyst Count
- UBX 2
- CLDI 3
- Target Price
- UBX $7.00
- CLDI $16.67
- AVG Volume (30 Days)
- UBX 303.9K
- CLDI 1.2M
- Earning Date
- UBX 11-04-2024
- CLDI 03-14-2025
- Dividend Yield
- UBX N/A
- CLDI N/A
- EPS Growth
- UBX N/A
- CLDI N/A
- EPS
- UBX N/A
- CLDI N/A
- Revenue
- UBX N/A
- CLDI N/A
- Revenue This Year
- UBX N/A
- CLDI N/A
- Revenue Next Year
- UBX $33.62
- CLDI N/A
- P/E Ratio
- UBX N/A
- CLDI N/A
- Revenue Growth
- UBX N/A
- CLDI N/A
- 52 Week Low
- UBX $0.94
- CLDI $0.73
- 52 Week High
- UBX $2.02
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- UBX 63.32
- CLDI 32.62
- Support Level
- UBX $1.56
- CLDI $0.83
- Resistance Level
- UBX $1.85
- CLDI $0.95
- Average True Range (ATR)
- UBX 0.22
- CLDI 0.12
- MACD
- UBX 0.05
- CLDI -0.03
- Stochastic Oscillator
- UBX 75.96
- CLDI 11.29
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.